肖侠明_好大夫在线

肖侠明

主任医师 教授

好大夫工作室 儿科

在线问诊 团队接诊 预约挂号 私人医生
微信扫码

微信扫码关注医生

有问题随时问

综合推荐热度 3.5

在线问诊量 387

左箭头 返回医生主页 门诊信息 患者投票 科普文章 患者问诊 心意礼物 患友会
肖侠明

肖侠明

主任医师 教授
在线问诊 团队接诊 预约挂号 私人医生
左箭头 返回医生主页 门诊信息 患者投票 科普文章 患者问诊 心意礼物 患友会

媒体报道

山西进行性肌营养不良少年志愿捐献全部器官

发表者:肖侠明 755人已读

2015年01月24日 新华网 

    新华网太原1月24日电(记者晏国政 马晓媛)“我的生命也许将不久于人世了,我是多想好好生活呀!可是,这样的病现在还没办法治愈,但我希望其他的生命能活得更好,我愿意捐出我的眼角膜、肾脏等所有对其他生命有用的器官。”


    这是18岁少年孔振宇在器官捐献申请中写下的一段话。好大夫工作室儿科肖侠明

    孔振宇出生在山西交口县韩家庄村一个普通农家。从小,家人就发现他和别的孩子不太一样,走路老是不稳,还经常摔跤。随着年龄渐长,振宇的身体越来越没有力气,到12岁时就只能躺在床上,靠父母照料。

    为了治病,一家人借了钱四处求医,却始终看不到希望。医生说,振宇患的是一种叫进行性肌营养不良的先天疾病,国际上也治不了,患者一般活不过20岁。

    面对残酷的命运,少年孔振宇依然感恩生命。他说曾经因为自己的不健康怨过父母,但如今最想对父母说一句谢谢——“谢谢你们给我生命。”

    得知自己可能将不久于人世,孔振宇提出了捐献器官的想法,希望用自己的生命帮助更多的人。但这个想法遭到了家人的反对。在观念保守的交口县,从未有过器官捐献的先例。父母心疼振宇“活着受病痛折磨,连走也走得不完整”,奶奶更是无法接受,觉得这样的事“太残忍”。

    为了说服父母,振宇软磨硬泡,甚至闹起绝食,父母拗不过他,终于同意。“孩子就这么一个心愿,他高兴就好。”母亲说。

    签志愿书那天,双手已经使不上劲的孔振宇在父母的帮助下,歪歪斜斜地写下自己的名字,接着开心地笑了。一旁的母亲转过头,偷偷擦着泪。当天中午,已经四五天没吃东西的振宇一口气吃下了大半碗面条。

    在孔振宇看来,生命这么珍贵,与其让它毫无意义的逝去,还不如用来帮助别人。“弟弟跟我的病一样,我也希望自己的身体用做医学研究,早日治好弟弟的病。”

    孔振宇一家的情况也引起当地政府的关注。目前,振宇兄弟俩在医院的一切花销都已免去,一家人还住进了县城的廉租房,省去了来回看病的长途奔波。众多爱心人士也为他们提供了各种形式的帮助。

    振宇的事在网上传开以后,感动了很多人。网友纷纷为他的善良、坚毅点赞,称他是“中国好少年”,更多人为他送上祝福,希望好人平安,还有热心的网友尝试为他的疾病提供帮助。

    “我的心里充满感恩。”孔振宇说,“我想,对父母和那些关心我的人最大的回报,就是珍惜生命,珍惜活着的每一天。”

Workshop on Theraputic Approaches for Duchenne Muscular Dystrophy

Background

The National Institute of Neurological Disorders and Stroke, the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the Office of Rare Diseases sponsored a workshop on the Therapeutic Approaches for Duchenne Muscular Dystrophy (DMD), May 15-16, 2000 in Bethesda, MD. Despite advances in knowledge to date on DMD, the life expectancy and quality of life for a child with DMD has not had substantial improvement since the gene was discovered. The Parent Project for Duchenne Muscular Dystrophy Research requested the help of NIH to promote research relevant to potential therapies, to encourage new scientists to the field of muscle biology research and to research on DMD, and to encourage NIH awareness and promote the importance of muscle research. In examining these issues, the goals of this workshop were to address key questions in improving treatments for DMD and identify areas of needed scientific knowledge, impediments, and critical next steps to promote effective therapy.

An international group of multidisciplinary scientists participated in the May 15-16th workshop. Representatives of the French (AFCM) and US (MDA) muscular dystrophy associations were present, as well as parent representatives from the US Parent Project for Duchenne Muscular Dystrophy Research and a European (German) foundation. The scientific organizers who aided in the development of the agenda were Dr. Louis Kunkel (Harvard), Dr. Lee Sweeney (U. Pennsylvania), Dr. Stanley Froehner (U. North Carolina), and Dr. Thomas Rando (Stanford). The workshop consisted of a round table format composed of 7 sessions, designed to encourage open discussion and develop recommendations to promote future research directions in DMD and muscle biology. (See attached Meeting Agenda and Participant List). A scientist chaired the discussion for each session's topics (topic leader for each session). After the scientific sessions were completed, participants were invited to remain to discuss issues of scientific review with representatives of the Center for Scientific Review (CSR), NIH. Summaries of the May 15-16th workshop presentations and CSR meeting are attached.

On May 17th, following the 2-day workshop of the 15-16th, the scientific organizers, topic leaders, and NIH program directors met to summarize the discussion from each session and formulate the future research priorities. Below is the summary of workshop discussions and identified future research priorities.


Priorities for Future Efforts

I. Mutation Detection/Diagnostics

A. Expand Molecular Characterization of the Duchenne Muscular Dystrophy (DMD) Population.
Many of the therapeutic approaches presented at this meeting, such as those using chimeraplasts (chimeric RNA/DNA oligonucleotides), antisense oligonucleotides, or amino glycoside antibiotics (see workshop summary) depend on precise knowledge of the dystrophin gene mutation in each patient with DMD. Thus, many of these therapeutic approaches will remain mutation-specific and therefore patient-specific. Current testing by most DMD diagnostic laboratories consists of deletion analysis, which has only about 65% sensitivity. Therefore, molecular characterization of the DMD population should be expanded. Duplication testing by Southern blot analysis or quantitative PCR (polymerase chain reaction) should be offered to all DMD patients. Low-cost, high-throughput DNA-based sequencing should be available to all DMD patients whose dystrophin genes do not have deletions or duplications. The resulting sequence data will not only be absolutely essential for determining specific therapy, but will also improve diagnostic sensitivity.

B. Consider Creatinine Kinase (CK) Screening of Newborns.
Physicians routinely screen at birth for certain metabolic disorders, such as the enzyme deficiency phenylketonuria, because early treatment is essential. Early detection of DMD might enable earlier intervention before the onset of irreversible muscle changes. This suggests the possibility of screening newborns for elevated CK activity, a characteristic of DMD. However, an objection to CK screening of newborns is that specific treatment does not exist for DMD. Furthermore, knowing that a newborn has screened positive might impose a psychological burden that makes it difficult for others in the family to bond with the newborn. Other concerns in newborn CK screening are the sensitivity and specificity of CK testing of samples taken 24 hours after birth, the number and quality of the laboratories doing the testing, and the cost of the test. Given these objections and concerns, it follows that the issue of newborn CK screening should be further considered, such as during a workshop on newborn screening or through a pilot research study.

II. Pathogenesis of Muscular Dystrophies

A. Animal Models and Central Repositories.
Additional studies on DMD pathogenesis are required to develop new areas of therapy that relate to the dystrophin-glycoprotein complex. Animal models might be useful for identifying novel and known genes that affect the phenotype of the muscular dystrophies, specifically DMD. The mouse and other species might be useful. Specifically, model genetic systems might also be helpful to determine the basic biology of the dystrophic process. Animal models or novel strains generated as part of these studies should be made available to all investigators to further DMD therapeutic studies. The role of a central repository for animal models, specifically for new and existing mouse models, should be considered.

B. Further Studies to Elucidate Both the Structural and the Signaling Role of Dystrophin-Glycoprotein Complex.
Studies suggest that the dystrophin-glycoprotein complex has both mechanical and signaling roles. Further studies to uncover downstream mediators associated with the dystrophic process are needed. These mediators might include known or novel signaling pathways. A number of new genes have been discovered that cause different genetic forms of muscular dystrophy. Overlapping disease mechanisms might lead to cell death in many of these similar disorders. Additionally, studies on novel alterations of the cytoskeleton, a critical internal structure of cells, in DMD and new methods to study novel alterations should be encouraged.

C. Role of the Immune System in DMD.
Further studies are needed on the specific immune response and on the nature of the inflammatory changes that accompany degeneration in DMD. Immunomodulatory effects of corticosteroids should be studied, given the effectiveness of these drugs in treating DMD. Additionally, specific studies should be considered on the role of corticosteroids in inflammation, and on the direct effect of corticosteroids on muscle stability and function and on stem cells, immature cells that retain the capacity to multiply and specialize to form new cells.

D. Cardiomyopathy, Vasculopathy, and Other Tissue Involvement.
Studies on the cardiomyopathy that accompanies DMD are needed because cardiac dysfunction significantly contributes to morbidity and mortality in DMD. The pathogenesis of cardiomyopathy--specifically, the role of vascular alterations--requires further study. Along these lines, examination is needed of the role of dystrophin-glycoprotein disruption in tissues other than striated muscle. These studies might include, but should not be limited to retina, brain, smooth muscle and vascular tissues. Additionally, the phenotype in DMD is variable. Identification of modifiers of phenotypic variability might lead to novel approaches to therapy.

III. Priorities for Gene Therapy Research

A. Delivery (viral mediated; naked DNA)
Results showed that DMD can be partly reversed by delivery of viral vectors into older mice. Presumably, more concentrated or efficient viral vectors could therefore achieve a complete reversal. The extent of reversal that can be achieved in late-stage patients remains unclear. Given the potential for reversal and the clear ability to prevent DMD, gene therapy techniques need to be studied further. However, technological advances to treat this disease need considerable refinement.

Four major areas need to be covered: (1) optimizing expression cassettes; (2) improving vector design; (3) managing immunologic consequences; and (4) optimizing delivery.

1. Optimizing Expression Cassettes
Expression cassettes that are introduced to cells for gene transfer therapies must include not only the gene to be transferred, the transgene, but also DNA elements that control the activity of the gene. A key issue in the organization of expression cassettes is in regulating the transgene, that is, the extent to which the transgene is expressed to produce mRNA which in turn is translated to protein. Regulating the transgene for maximal expression requires understanding which enhancers, promoters, introns, and polyadenylation signals affect the transgene's expression and should be included in the cassette. Tissue-specific gene expression also needs to be understood in designing a cassette.

Another key issue is to decide on which gene or DNA is to be delivered. This is of particular concern in working with large genes such as utrophin and dystrophin where a shorter version of the gene may be more efficient for therapy. The mRNA (messenger RNA) that cells copy from the DNA code includes regions that are cut out before the RNA is translated to make protein. Research is needed on the relationships between structure and function of untranslated regions in dystrophin and utrophin mRNAs and between structure and function in dystrophin and utrophin proteins. The use of the best start and stop codons (the gene code signals to begin and terminate protein translation) and the introduction of heterologous untranslated regions also need to be considered.

2. Improving Vector Design
Vector design clearly needs improvement. The ability of a vector to target or deliver to muscle needs to be considered. This includes whether the vector is or is not infectious, replicating, and integrating. The cloning capacity of vectors needs to be considered, e.g., if vectors can transport small or large genes, or multiple genes. The effect of the persistence of a vector needs to be considered, to include comparing episomal vectors with integrated vectors, measuring stabilization of vector retention, and determining replication competence. Finally, the safety of vectors needs to be determined.

3. Managing Immunologic Considerations
Immunologic considerations include comparisons between normal and dystrophic muscle with regard to the type, presence, and recruitment of immune cells. Immunologic considerations also include characterizing, modulating, and avoiding the response against vectors and against the transgenes themselves. For example, one question is to compare the immunogenicity of transgenes containing the dystrophin gene with the immunogenicity of transgenes containing the utrophin gene.

4. Optimizing Delivery
Delivery is ultimately "the rate-limiting step" in determining the success of gene therapy. It might be difficult to target an expression cassette to all muscles of the body. Route of administration, such as local or systemic, needs to be considered. Targeting vectors to muscle while avoiding other cells might need to be accomplished. Dosing regimens need to be worked out.

B. Alternative (Non-viral) Genetic Therapies

1. Summary of Non-Viral Molecular Mechanisms.
The unifying theme of the session on alternative (non-viral) mediated therapies was that each therapeutic approach uses different molecular mechanisms to target the endogenous dystrophin gene. These approaches include chimeraplasts, antisense nucleotides, and aminoglycoside antibiotics. Chimeraplasts are specifically designed synthetic hybrids of DNA and RNA that can induce the cell's DNA repair machinery to make corrections in a particular sequence of a cell's DNA. Antisense nucleotides, also designed with a sequence that complements a specific region of DNA, can affect which parts of the messenger RNA are skipped and which copied to make protein. Aminoglycoside antibiotics can suppress stop codons introduced by mutations that improperly terminate code for the dystrophin protein. A discussion of peptide translocation domains was presented in the context of delivery mechanisms for oligonucleotides and therapeutic peptides.

The most notable conclusion was that novel therapies might emerge unexpectedly from research that is not directed at developing therapies. Each of the discussed therapies arose from research that had nothing to do with muscular dystrophy or with therapeutics in general. Thus, the emergence of these therapies provides rationale for not focusing too much effort or too many resources solely on research directed at developing therapies. Therapy for DMD in the future is likely to encompass both a combination of approaches currently being studied with approaches not yet even conceived.

2. Research in Delivery and Targeting in Oligonucleotide-Based Therapy.
One specific recommendation is to consider oligonucleotides (used here to include chimeraplasts, antisense oligonucleotides, and plasmid DNA) as drugs and to support research in the emerging area of oligonucleotide-based therapy. As with advances in viral-mediated therapies, advances in non-viral-mediated therapies need to come in two areas. The first is in methods of systemic delivery, including packaging the oligonucleotides for stability, cellular uptake, and bioavailability. The second is in methods of targeting oligonucleotides specifically to muscle, primarily for the purpose of efficiency. Research in systemic delivery and in targeting gene therapy vectors should include studies on oligonucleotide-based therapy.

3. Role of Immune System.
As with viral-mediated therapies, non-viral mediated therapies might enable the production of "new" dystrophin in a boy with DMD, with the ensuing possibility that his immune system will respond to it. The importance of studying the role of immune responses to dystrophin is the same whether or not the therapy is viral-mediated. This further emphasizes the need to include the immunology of DMD within the scope of research efforts.

4. Oligonucleotide-Based Therapy Requires Molecular Genetic Information for Each Individual with DMD.
Finally, each therapeutic modality discussed (chimeraplasts, antisense oligonucleotides, aminoglycoside antibiotics) is applicable to DMD arising only from certain kinds of dystrophin mutations. This emphasizes the need to have accurate genetic data for each patient.

IV. Questions for Gene Therapy Research

Research needed on stem cell therapy for muscular dystrophy can be summarized in the questions formatted as follows:

  1. What is the nature of the cells? What is their origin and developmental state?

  2. How can the cells be purified? What markers can be used for purification? Is Hoescht's staining a sufficient marker?

  3. What surface markers are the cells expressing? Is there a lineage relationship that needs to be worked out?

  4. How can cells be cultured, their developmental potential expanded and maintained?

  5. Can cells be delivered from circulation? Can cells be recruited in sufficient quantities from the circulation to be efficacious? (Currently, only about 10% can be recruited, which is insufficient.)

  6. What is the developmental potential of cells? Is it necessary to use the earliest stage cells, or will later stage cells suffice? Which is preferable, autologous or heterologous engraftment?

  7. What must be done to make cells therapeutically useful?

 

V. Pharmacologic Therapy

A. High-Throughput Screening.
High-throughput screening is an approach to drug development that employs robotics to rapidly screen thousands of chemical compounds in miniaturized assays (tests) to find leads for further testing. High throughput technology is used extensively in industry but less so in academia. A consortium of academic and industrial groups would probably better accomplish development of high-throughput methods for DMD.

B. Assess Steroid Trials and Design Definitive Trials.
Results from smaller trials of prednisone have not been conclusive. Therefore, one strong recommendation is to convene a 1-day workshop to evaluate steroids and design definitive trials. For example, larger, definitive trials with better controls, such as a trial that compares prednisone-dosing regimens, are needed to evaluate the use of prednisone. Trials of deflazacort should also be considered.

C. Understanding the Immunology of DMD.
Research in various basic subjects is needed. Given that prednisone is an immunosuppressive drug, the immunology of DMD needs to be better understood. Further understanding of how prednisone works could lead to the introduction of better drugs. Animal models could be used for studies of various DMD drugs.

VI. Resources and Future Directions

A. Non-invasive Muscle Imaging Techniques.
Imaging techniques should be improved so that they better diagnose DMD and monitor disease course during treatment, thus rendering repeated muscle biopsies unnecessary.

B. Development of Efficient Means to Test Potential Therapies in Clinical Trials.
The escalating costs of gene therapy trials might force academic centers to discontinue doing them and result in fewer trials being done. With regards to new therapeutic compounds, an additional concern is that, upon learning about a trial of a test compound, families/patients may forego participating and instead simply try to obtain the compound. Therefore, centers need to cooperate to move trials more quickly.

C. Developing a Centralized Web Base for Accessing Information.
A centralized Web site providing a database should be made available to facilitate knowledge of what clinical information, tissue, reagents, and resources are available for DMD research.

D. General Issues.
Research on muscle biology should be encouraged. Also, much could probably be learned by studying dystrophin and utrophin in tissues other than muscle, such as dystrophin complexes in brain and utrophin in epithelial cells. Vascular abnormalities in the retina should be studied.


本文为转载文章,如有侵权请联系作者删除。

问医生

图文问诊开始

×
分享到微信
打开微信“扫一扫”,即可分享该文章

发表于:2015-01-24 10:57

肖侠明大夫的信息

  • 感谢信: 0 感谢信 礼物: 0 礼物

网上咨询肖侠明大夫

肖侠明医生暂时不接受网络咨询

肖侠明的咨询范围: 仅提供免费咨询,不接受付费咨询。